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Lung Adenocarcinomas with HER2-Activating Mutations
Are Associated with Distinct Clinical Features and HER2/
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Rui Wang, MD,*† Yunjian Pan, MD,*† Haichuan Hu, MD,*† Yang Zhang, MD,*† William Pao, MD,§
Lei Shen, MD,† Hongbin Ji, PhD,‡ and Haiquan Chen, MD*†
Introduction: A fraction of lung adenocarcinomas harbor activating
mutations in the HER2 kinase domain. HER2-targeted therapies
have shown minimal benefit in molecularly unselected patients. We
investigated clinical and potential molecular factors associated with
HER2-mutant lung adenocarcinoma.
Methods: A total of 224 lung adenocarcinoma samples were examined
for activating mutations in epidermal growth factor receptor (EGFR;
exons 18–22), V-Ki-ras2 Kirsten rat sarcoma (KRAS; exons 2 and 3),
andHER2 (exons 18–21) by direct sequencing. Gene copy number and
protein expression of both EGFR and HER2 were further explored in
samples harboring HER2 mutations using fluorescence in situ
hybridization and immunohistochemistry, respectively.
Results: The mutation rates of EGFR, KRAS, HER2 were 63.39%
(142/224), 4.46% (10/224), and 3.57% (8/224), respectively. All
mutations were mutually exclusive. All eight HER2 mutations oc-
curred in never smokers and seven were in women. TheHER2mutation
rate in samples without EGFR and KRASmutations was 11.11% (8/72).
Seven of eight HER2-mutated tumors showed HER2 copy number
gains (CNGs) and five showed EGFR CNGs. All of the HER2-mutated
samples showed either HER2 or EGFR CNGs. Gene amplification of
HER2 and EGFR was mutually exclusive in HER2-mutated samples.
Conclusion: HER2 mutations in lung adenocarcinoma predomi-
nantly occurred in women and never smokers. Most HER2-mutated
tumors showed HER2 CNGs. As all of the samples with HER2
mutation showed either HER2 or EGFR CNGs, these patients could
potentially benefit from novel EGFR/HER2 dual or pan-erythroblas-
tic leukemia viral oncogene homolog tyrosine kinase inhibitors.
Key Words: HER2, Lung adenocarcinoma, Mutation, Copy num-
ber, EGFR, KRAS.
(J Thorac Oncol. 2012;7: 85–89)
Lung cancer is the leading cause of cancer-related deathworldwide.1,2 Lung cancer is divided into four subtypes
according to histologic features: adenocarcinoma, squamous
carcinoma, large-cell carcinoma, and small-cell carcinoma.
The first three subtypes are grouped together as non-small
cell lung cancer (NSCLC), which accounts for approximately
80 to 85% of all lung cancers, and adenocarcinoma is the
most common subtype of NSCLC.1,3 Despite advances in
screening and multimodality therapies, the 5-year survival
rate (10–15%) remains low.1,4
HER2 (also known as epidermal growth factor recep-
tor-2 [EGFR2], ERBB2, or NEU) is a member of the ERBB
family of receptor tyrosine kinases, which also includes
EGFR (HER1/ERBB1), HER3 (ERBB3), and HER4 (ERBB4).
EGFR and HER2 are found to be deregulated and drive many
human cancers. Deregulation of HER2, involving kinase
domain mutation, copy number gain (CNG), and protein
overexpression, is reported in 1.6 to 4%, 2 to 22.8%, and 11
to 32% of NSCLCs.5–10 In our previous study, 90% of lung
adenocarcinoma from never smokers harbored an oncogenic
driver mutation, in which HER2 mutation was present in
3.8% of patients.11
Agents targeting EGFR and HER2 are widely used to
treat epithelial cancers of lung, breast, colon, and head and
neck cancers.12,13 The experience from EGFR tyrosine kinase
inhibitors (TKIs) in NSCLC has demonstrated that clinical
benefit from targeted therapy is easily diluted by subgroups
with specific molecular features. Clinical trials targeting
HER2 in NSCLC have mainly focused on protein expression
and CNG. Using this approach, disappointing results were
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seen in the trials using trastuzumab and lapatinib.10,14 Studies
for specific patients with HER2-activating mutations are on-
going. We hypothesized that HER2 mutations could be asso-
ciated with other molecular alterations involving HER2 or
EGFR. In this study, we sought to identify the HER2 muta-
tion rate and associated clinical characteristics in Chinese
patients. We further explored both HER2 and EGFR copy
number variation and protein expression levels in HER2-
mutated samples.
MATERIALS AND METHODS
Chinese Lung Adenocarcinoma Specimen
Collection
From September 2007 to October 2009, a total of 224
lung adenocarcinomas were consecutively collected at Fudan
University Shanghai Cancer Center, Shanghai, China. All
participants gave informed consent. Samples were snap-
frozen and stored in liquid nitrogen at the time of resection
until use. Every sample was determined as a primary lung
adenocarcinoma by pathologists. No patients received neo-
adjuvant treatment. This study was approved by the Ethics of
Human Research Committee of Fudan University Shanghai
Cancer Center.
Polymerase Chain Reaction Amplification and
Polymerase Chain Reaction Product Direct
Sequencing
EGFR, HER2, and V-Ki-ras2 Kirsten rat sarcoma
(KRAS) status were assessed as published.11Exons 18 to 21
of HER2 were analyzed by polymerase chain reaction
(PCR) amplification and direct sequencing of PCR products.
The forward PCR primer was 5-CCCTCTGACGTCCAT-
CATCT-3, the reverse primer was 5-GCAGGGTCTGGA-
CAGAAGAA-3, and the sequencing primer was 5-
GGTCTTTGGGATCCTCATCA-3. PCR amplification was
done with Thermococcus kodakaraensis plus polymerase
(Toyobo, Japan), with initial denaturation at 94°C for 4 minutes,
35 cycles each consisting of denaturation at 94°C for 30 seconds,
annealing at 61°C for 30 seconds, and strand elongation at 68°C
for 1 minute performed to amplify DNA fragments followed by
a final elongation at 68°C for 10 minutes. All samples found to
have a genetic alteration in the target were subsequently verified
by genomic DNA sequencing.
Fluorescence In Situ Hybridization
HER2 and EGFR gene copy numbers per cell were
detected in formalin-fixed paraffin-embedded specimens by
fluorescence in situ hybridization (FISH). HER2 FISH was
performed using the LSI HER2 spectrum orange/CEP17
spectrum green probe (Beijing GP Medical Technologies,
Inc., Beijing, People’s Republic of China). EGFR FISH was
done using the LSI EGFR Spectrum orange/CEP7 Spectrum
green probe (Vysis; Abbott Laboratories, Abbott Park, IL).
FISH was performed on the same tissue specimens subjected
to sequencing. At least 50 cells were analyzed for each case
by two pathologists. HER2 and EGFR gene copy numbers
were classified according to the published criteria as disomy,
low polysomy (4 copies of EGFR in 40% of cells), high
polysomy (4 copies of EGFR in 40% of cells), or gene
amplification (homogenously staining regions with 15
copies in 10% of cells [or a gene/chromosome ratio per
cell of 2]).7,15
Immunohistochemistry Staining
Paraffin-embedded tissue sections were analyzed for
EGFR and HER2 protein expression by immunohistochem-
istry (IHC) using anti-EGFR and -HER2 antibodies (Bio-
world Technology, Inc., St. Louis Park, MN). HER2 IHC
results were interpreted as follows: 0, no staining; 1, weak,
membranous staining; 2, moderate membranous staining of
at least 10% of invasive tumor cells; and 3, strong mem-
branous staining of at least 10% of invasive tumor cells.
Cases interpreted as 0 or 1 were considered negative, and
cases interpreted as 2 or 3 were considered positive.
Samples with more than 10% tumor cells showing membra-
nous staining of any intensity were classified as EGFR
positive as reported before.16
Statistical Analysis
The association between EGFR status and clinical and
biological characteristics was analyzed by 2 or Fisher’s
exact test tests. Age differences were compared using the t
test for independent samples. All data were analyzed using
the Statistical Package for the Social Sciences Version 16.0
Software (SPSS Inc., Chicago, IL). The two-sided signifi-
cance level was set at p less than 0.05.
RESULTS
Spectrum of EGFR, KRAS, and HER2 Mutations
in Lung Adenocarcinoma from a Chinese
Population
The mutation rates of EGFR, KRAS, and HER2 were
63.39% (142/224), 4.46% (10/224), and 3.57% (8/224), re-
spectively (Figure 1). Mutations in these three genes were
mutually exclusive. Only 28.57% (64/224) of samples lacked
a detectable mutation in these three genes. In the eight
FIGURE 1. Pie chart of EGFR, KRAS, and HER2 mutation
spectrum from 224 lung adenocarcinomas. The mutation
rates of EGFR, KRAS, and HER2 were 63.39, 4.46, and 3.57%,
respectively. A total of 28.57% of samples lacked a detect-
able mutation in these three genes.
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samples harboring HER2 kinase domain mutations, all were
exon 20 776 to 779 YVMA insertions.
Clinical Characteristics of Patients with HER2
Mutations
Clinical information on the 224 patients with lung
adenocarcinoma is listed in Table 1. There were 114 men and
110 women. The HER2 mutation rate in samples without
EGFR and KRAS mutation was 11.11% (8/72). All eight
tumors with HER2 mutations were from never smokers (p 
0.028). HER2 mutations were predominantly seen in women
(7/8) (Table 2). Detailed information on the eight patients
with HER2 mutation is listed in Table 3. Six of eight had
stage III disease, all involving mediastinal lymph nodes,
suggesting that HER2 mutation may be an unfavorable prog-
nostic factor; however, the number of patients studied was
too small to make a definitive association.
HER2 and EGFR Copy Number Variations and
Protein Expression in HER2-Mutated Samples
Five of eight samples were EGFR FISH positive, in-
cluding one with EGFR gene amplification and four with
chromosome 7 high polysomy (Figure 2A, B). Seven of eight
samples were HER2 FISH positive, including four with gene
amplification and three with chromosome 17 high polysomy
(Figure 2C, D). All of the HER2-mutated samples showed
either HER2 or EGFR CNGs (Table 3). Three of the samples
showed both chromosome 17 and 7 high polysomy, and five
samples showed either HER2 or EGFR amplification. Gene
amplification of HER2 and EGFR was mutually exclusive.
HER2 and EGFR protein overexpression was seen in two and
four samples, respectively (Table 3).
DISCUSSION
During the past decade, increasing evidence has shown
that lung adenocarcinoma is composed of distinct molecular
subsets,11,17–19 including those defined by mutated oncogenes
such as EGFR,20 KRAS,21 HER2,9 EML4-ALK,22 and ROS1.23
Except for KRAS, all subsets can be treated with targeted
agents in clinical use or under trial. HER2 mutations have
been reported to exist in up to 4% of NSCLCs. Considering
the large amount of patients with this alteration (equivalent to








Smoking history, n (%)
Never smoker 139 (62.05)











TABLE 2. Correlation between HER2 Mutation and Age,
Gender, and Smoking Habit
HER2 Mutational Status
pMutation Wild Type
No. of patients 8 216
Median age, yr  SD 53  6.27 57.77  9.84 0.176
Gender
Male 1 107 0.67
Female 7 109
Smoking habit
Never smoker 8 134 0.028
Ever smoker 0 82
SD, standard deviation.









FISH Gender Age (yr) Smoke Subtype Differentiation Stages Stages
6  HP/  HP/ Female 59 No Mucinous M T2N2M0 IIIa
43  HP/  HP/ Female 48 No L T2aN2M0 IIIa
216  HP/  HP/ Female 49 No H-M T2aN2M0 IIIa
231  Amp/  LP/ Male 64 No M-L T4N2M0 IIIb
280  Amp/  LP/ Female 52 No M-L T1bN2M0 IIIa
469  Dis/  Amp/ Female 45 No Mucinous M T2aN0M0 Ib
575  Amp/  HP/ Female 52 No M-L T2bN2M0 IIIa
583  Amp/  LP/ Female 57 No M T2aN0M0 Ib
HP, high polysomy; LP, low polysomy; Dis, disomy; Amp, amplification; M, moderate; L, low; H, high; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization;
EGFR, epidermal growth factor receptor.
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those with ALK fusions), a thorough understanding of the
disease entity is needed.
HER2mutations in NSCLC occur in the first four exons
of the tyrosine kinase domain (exons 18–21).5 All of the eight
HER2 mutations in this study were found in exon 20, involv-
ing a 12-bp duplication/insertion coding of the amino acid
YVMA. In previous studies,5,24 the YVMA insertion has also
been found to be the most common alteration. Similar to
EGFR mutations, HER2 mutations are more common in
Asians, adenocarcinomas, women, and never smokers.5,11,24
All of the eight patients with HER2 mutation in this study
were never smokers, and seven of eight patients were women.
Furthermore, consistent with previous studies, EGFR, KRAS,
and HER2 mutations were all mutually exclusive in this
analysis.
Enlightened by the great success of EGFR TKIs in
EGFR-mutated NSCLCs, novel agents targeting ALK and
HER2 are under study in clinical trials.9,25 There are a number
of agents targeting HER2. Trastuzumab, a humanized mono-
clonal antibody against the HER2 extracellular domain, failed
to show a benefit in patients defined by IHC, but yielded
dramatic shrinkage of tumors harboring HER2 mutation.26,27
Reversible and irreversible TKIs targeting EGFR/HER2 in-
clude lapatinib, BIBW 2992, and neratinib. Another irrevers-
ible inhibitor, PF00299804, inhibits all ERBB family mem-
bers with kinase activity.14,28–30 Cells harboring HER2
mutations are sensitive to TKIs targeting both EGFR and
HER2 (HKI-272, Wyeth, Madison, NJ), but not to those that
only target EGFR.31 These studies indicate that small-mole-
cule agents targeting both EGFR and HER2 could be used for
both EGFR-TKI-resistant and HER2-mutated tumors. Studies
with these agents in NSCLC are ongoing.
CNGs defined by FISH may be another important
predictive factor for targeted therapy. Cappuzzo et al.7 re-
ported that increased copy number of HER2 is associated
with response to gefitinib in patients with NSCLC. In the
eight samples with HER2 mutation in this study, seven
showed HER2 CNG and five showed EGFR CNG. The only
sample without CNG of HER2 showed EGFR amplification.
Although the sample size was small and this study was
retrospective, our findings may help shed light on interpreta-
tion of results from trials targeting HER2-mutant tumors.
CONCLUSION
We have studied the HER2 mutation status in a cohort
of patients with lung adenocarcinoma from a Chinese popu-
lation. In the eight samples with HER2 mutations, we have
also characterized EGFR and HER2 protein status by IHC
and gene status by FISH. HER2 mutations could define a
subgroup of patients with lung adenocarcinoma who share
clinical features with EGFR-mutated cases but that would
benefit from EGFR/HER2 dual or pan-ERBB TKIs.
ACKNOWLEDGMENTS
Supported by the National Basic Research Program of
China (2010CB912102), Wu Jieping Medical Foundation
(320.6740.10020), the National Natural Science Foundation
of China (30871284 and 30971461), the Chinese Academy of
Sciences (KSCX1-YW-22), and the Science and Technology
Commission of Shanghai Municipality (08PJ14105 and
09JC1416300). H.J. is a scholar of the Hundred Talents
Program of the Chinese Academy of Sciences.
REFERENCES
1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin
2010;60:277–300.
2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer
J Clin 2011;61:69–90.
3. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med
2008;359:1367–1380.
4. Sant M, Aareleid T, Berrino F, et al. EUROCARE-3: survival of cancer
patients diagnosed 1990–94—results and commentary. Ann Oncol
2003;14(Suppl 5):v61–v118.
5. Shigematsu H, Takahashi T, Nomura M, et al. Somatic mutations of the
HER2 kinase domain in lung adenocarcinomas. Cancer Res 2005;65:
1642–1646.
6. Stephens P, Hunter C, Bignell G, et al. Lung cancer: intragenic ERBB2
kinase mutations in tumours. Nature 2004;431:525–526.
7. Cappuzzo F, Varella-Garcia M, Shigematsu H, et al. Increased HER2
gene copy number is associated with response to gefitinib therapy in
epidermal growth factor receptor-positive non-small-cell lung cancer
patients. J Clin Oncol 2005;23:5007–5018.
8. Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in
non-small cell lung cancer: a comprehensive evaluation by real time
reverse transcription-PCR, fluorescence in situ hybridization, and im-
munohistochemistry. Clin Cancer Res 2003;9:3645–3652.
9. Swanton C, Futreal A, Eisen T. Her2-targeted therapies in non-small cell
lung cancer. Clin Cancer Res 2006;12:4377s–4383s.
10. Langer CJ, Stephenson P, Thor A, et al. Trastuzumab in the treatment of
advanced non-small-cell lung cancer: is there a role? Focus on Eastern Coop-
erative Oncology Group study 2598. J Clin Oncol 2004;22:1180–1187.
11. Sun Y, Ren Y, Fang Z, et al. Lung adenocarcinoma from East Asian
FIGURE 2. Cases showing CNGs of EGFR and HER2 de-
tected by FISH. A, High polysomy of EGFR, with 4 copies of
EGFR in 40% of nuclei counted. B, EGFR amplification
showing an EGFR gene/chromosome 7 ratio 2 in 10%
cells. C, High polysomy of HER2, with 4 copies of HER2 in
40% of nuclei counted. D, HER2 amplification showing a
HER2 gene/chromosome 17 ratio 2 in 10% cells.
Li et al. Journal of Thoracic Oncology • Volume 7, Number 1, January 2012
Copyright © 2011 by the International Association for the Study of Lung Cancer88
never-smokers is a disease largely defined by targetable oncogenic
mutant kinases. J Clin Oncol 2010;28:4616–4620.
12. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal
growth factor receptor underlying responsiveness of non-small-cell lung
cancer to gefitinib. N Engl J Med 2004;350:2129–2139.
13. Normanno N, Bianco C, De Luca A, et al. Target-based agents against
ErbB receptors and their ligands: a novel approach to cancer treatment.
Endocr Relat Cancer 2003;10:1–21.
14. Ross HJ, Blumenschein GR Jr, Aisner J, et al. Randomized phase II
multicenter trial of two schedules of lapatinib as first- or second-line
monotherapy in patients with advanced or metastatic non-small cell lung
cancer. Clin Cancer Res 2010;16:1938–1949.
15. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal
growth factor receptor gene copy number detected by fluorescence in
situ hybridization associates with increased sensitivity to gefitinib in
patients with bronchioloalveolar carcinoma subtypes: a Southwest On-
cology Group Study. J Clin Oncol 2005;23:6838–6845.
16. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in non-small-
cell lung cancer: analysis of a large series of cases and development of a
rapid and sensitive method for diagnostic screening with potential implica-
tions on pharmacologic treatment. J Clin Oncol 2005;23:857–865.
17. Weir BA, Woo MS, Getz G, et al. Characterizing the cancer genome in
lung adenocarcinoma. Nature 2007;450:893–898.
18. Director’s Challenge Consortium for the Molecular Classification of
Lung Adenocarcinoma; Shedden K, Taylor JM, Enkemann SA, et al.
Gene expression-based survival prediction in lung adenocarcinoma: a
multi-site, blinded validation study. Nat Med 2008;14:822–827.
19. Ding L, Getz G, Wheeler DA, et al. Somatic mutations affect key
pathways in lung adenocarcinoma. Nature 2008;455:1069–1075.
20. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy
for non-small-cell lung cancer with mutated EGFR. N Engl J Med
2010;362:2380–2388.
21. Massarelli E, Varella-Garcia M, Tang X, et al. KRAS mutation is an
important predictor of resistance to therapy with epidermal growth factor
receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin
Cancer Res 2007;13:2890–2896.
22. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming
EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;
448:561–566.
23. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine
signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:
1190–1203.
24. Tomizawa K, Suda K, Onozato R, et al. Prognostic and predictive
implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung
Cancer. 2011;74:139–144.
25. Ou SH, Bazhenova L, Camidge DR, et al. Rapid and dramatic radio-
graphic and clinical response to an ALK inhibitor (crizotinib,
PF02341066) in an ALK translocation-positive patient with non-small
cell lung cancer. J Thorac Oncol 2010;5:2044–2046.
26. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of
gemcitabine-cisplatin with or without trastuzumab in HER2-positive
non-small-cell lung cancer. Ann Oncol 2004;15:19–27.
27. Cappuzzo F, Bemis L, Varella-Garcia M. HER2 mutation and response
to trastuzumab therapy in non-small-cell lung cancer. N Engl J Med
2006;354:2619–2621.
28. Yap TA, Vidal L, Adam J, et al. Phase I trial of the irreversible EGFR
and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid
tumors. J Clin Oncol 2010;28:3965–3972.
29. Godin-Heymann N, Ulkus L, Brannigan BW, et al. The T790M “gate-
keeper” mutation in EGFR mediates resistance to low concentrations of
an irreversible EGFR inhibitor. Mol Cancer Ther 2008;7:874–879.
30. Engelman JA, Zejnullahu K, Gale CM, et al. PF00299804, an irrevers-
ible pan-ERBB inhibitor, is effective in lung cancer models with EGFR
and ERBB2 mutations that are resistant to gefitinib. Cancer Res 2007;
67:11924–11932.
31. Wang SE, Narasanna A, Perez-Torres M, et al. HER2 kinase domain
mutations results in constitutive phosphorylation and activation of HER2
and EGFR and ressistance to EGFR tyrosine kinase inhibitors. Cancer
Cell 2006;10:25–38.
Journal of Thoracic Oncology • Volume 7, Number 1, January 2012 Lung Adenocarcinomas with HER2-Activating Mutations
Copyright © 2011 by the International Association for the Study of Lung Cancer 89
